Srdan Verstovsek, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the updated data from the Phase II MANIFEST study (NCT02158858): a trial of novel epigenetic modifier pelabresib (CPI-0610) in combination with ruxolitinib (rux) in myelofibrosis. Pelabresib is a first-in-class inhibitor of bromodomain and extraterminal domain (BET) proteins, which regulate gene transcription in numerous pro-fibrotic pathways. The combination was well-tolerated. The results provide evidence of synergy between pelabresib and rux in these myelofibrosis patients, and the spleen and symptom benefits are promising. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

свернуть